THEODORE OSUALA: Open Payments
NPI 1356428833 · LANHAM, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,246 in 86 payments from 14 companies in 2025. Trend: 2023 $837 · 2024 $1,185 · 2025 $2,246
Food & beverage: $2,222Education: $24
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $605 |
| Neurocrine BioSciences, Inc. | 5 | $245 |
| Otsuka America Pharmaceutical, Inc. | 10 | $243 |
| ABBVIE INC. | 10 | $207 |
| Lundbeck LLC | 9 | $205 |
| Vanda Pharmaceuticals Inc. | 7 | $185 |
| E.R. Squibb & Sons, L.L.C. | 11 | $178 |
| Teva Pharmaceuticals USA, Inc. | 7 | $151 |
| Janssen Pharmaceuticals, Inc | 5 | $139 |
| Tris Pharma Inc | 1 | $21 |
Products named: CAPLYTA, REXULTI, INGREZZA, VRAYLAR, COBENFY, ABILIFY ASIMTUFII, INVEGA SUSTENNA, FANAPT.
Industry payments across MD — which companies pay providers there.
